AGN - Allergan plc

NYSE - Nasdaq Real-time price. Currency in USD
186.29
+2.00 (+1.09%)
As of 3:07PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close184.29
Open184.19
Bid186.10 x 800
Ask186.17 x 900
Day's range184.35 - 186.52
52-week range142.81 - 223.04
Volume1,782,838
Avg. volume1,675,535
Market cap63.235B
Beta1.37
PE ratio (TTM)N/A
EPS (TTM)-5.32
Earnings date30 Oct 2018 - 5 Nov 2018
Forward dividend & yield2.88 (1.52%)
Ex-dividend date2018-08-16
1y target est210.15
Trade prices are not sourced from all markets
  • A Review of Pharma Stocks’ EPS Growth Rates
    Market Realist5 hours ago

    A Review of Pharma Stocks’ EPS Growth Rates

    In this article, we’ll compare the EPS growth rates of pharmaceutical companies Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018
    Market Realistyesterday

    These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018

    The US pharmaceutical sector is made up of players that include drug manufacturers, drug marketers, and biotechnology companies.

  • Allergan Frown Lines Study Passes Test on Higher Botox Dose
    Zacksyesterday

    Allergan Frown Lines Study Passes Test on Higher Botox Dose

    Allergan (AGN) presents positive results from a study, evaluating a higher dose of Botox for the treatment of glabellar lines.

  • FDA plans meeting to discuss safety data on breast implants
    Associated Press4 days ago

    FDA plans meeting to discuss safety data on breast implants

    U.S. health regulators say they'll convene a public meeting of medical advisers next year to discuss new science on breast implant safety, including an independent analysis that suggests certain rare health problems might be more common with silicone gel implants.

  • Who Really Owns Allergan plc (NYSE:AGN)?
    Simply Wall St.4 days ago

    Who Really Owns Allergan plc (NYSE:AGN)?

    A look at the shareholders of Allergan plc (NYSE:AGN) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual toRead More...

  • Is Allergan (AGN) a Great Stock for Value Investors?
    Zacks4 days ago

    Is Allergan (AGN) a Great Stock for Value Investors?

    Let's see if Allergan (AGN) stock is a good choice for value-oriented investors right now from multiple angles.

  • Allergan Unveils Spotlyte, Its First Digital Ventures Launch
    Market Realist5 days ago

    Allergan Unveils Spotlyte, Its First Digital Ventures Launch

    On September 12, Allergan (AGN) announced the launch of Spotlyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit. Spotlyte is an innovative digital hub designed to educate consumers about medical aesthetic treatments. The below chart lists key updates on Spotlyte. Spotlyte is the first venture from Project Moonwalker and is designed to educate consumers about medical aesthetics.

  • Why Bausch Health Companies Inc. Stock Is Booming Today
    Motley Fool6 days ago

    Why Bausch Health Companies Inc. Stock Is Booming Today

    Settlement of patent litigation provides a spark for Bausch Health.

  • 56% of Analysts Recommend a ‘Buy’ for Editas Medicine
    Market Realist8 days ago

    56% of Analysts Recommend a ‘Buy’ for Editas Medicine

    In August, the National Institutes of Health’s (or NIH) recombinant DNA advisory committee completed the NIH protocol for Editas Medicine’s (EDIT) EDIT-101. EDIT-101 is an investigational CRISPR genome editing therapy for the treatment of individuals with LCA10 (Leber Congenital Amaurosis type 10). Editas Medicine plans to submit an IND (Investigational New Drug) application to the FDA in October.

  • Allergan Launches the SkinMedica Lumivive System
    Market Realist11 days ago

    Allergan Launches the SkinMedica Lumivive System

    On September 6, Allergan (AGN) announced the launch of its new innovative dual-acting product, the SkinMedica Lumivive System. Lumivive is an innovative skincare product that works as a shield from blue light during the day and an essential skin repair process at night. The Lumivive System offers atmospheric protection during the day and fights the signs of aging for optimal skin health.

  • Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy
    Market Realist12 days ago

    Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

    Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating the investigational Lenti-D gene therapy for the treatment of cerebral adrenoleukodystrophy (or CALD) in boys aged 17 years or less. The Phase 2/3 Starbeam study met its enrollment goal with the data reported by Bluebird Bio as of April 25. Thirty-one patients were studied, and 29 of them received Lenti-D gene therapy.

  • Glaukos Stock Rose 40.3% on August 29
    Market Realist19 days ago

    Glaukos Stock Rose 40.3% on August 29

    Glaukos’ (GKOS) share price rose ~40.3% and closed at $62.86 on August 29. The increase was a reaction to the news from Novartis’ (NVS) Alcon business unit about the immediate and voluntary withdrawal of its CyPass Micro-Stent across the world on June 29. In July 2016, the CyPass Micro-Stent was approved by the FDA to be used along with cataract surgery for patients suffering from mild-to-moderate primary open-angle glaucoma. The reduced competition for Glaukos’ glaucoma devices caused Robbie Marcus, a JPMorgan Chase analyst, to increase the company’s target price to $75, which implies an upside potential of ~19.3%—compared to the company’s last closing price.

  • Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs
    Zacks25 days ago

    Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs

    Allergan (AGN) gets CRL for uterine fibroids candidate, Esmya. Merck (MRK) and Bristol-Myers' (BMY) PD-L1 inhibitors get FDA approval for expanded labels.

  • 3 Relatively Safe Ways to Invest in Gene Editing
    Motley Fool25 days ago

    3 Relatively Safe Ways to Invest in Gene Editing

    Here's how you could profit from gene editing without buying the stocks of preclinical-stage biotechs.

  • AbbVie Posts Positive Data on Elagolix for Uterine Fibroids
    Zacks26 days ago

    AbbVie Posts Positive Data on Elagolix for Uterine Fibroids

    AbbVie (ABBV) reports positive top-line results from a phase III extension trial on its investigational candidate Elagolix for treating uterine fibroids in women.

  • Investor's Business Daily27 days ago

    Stocks Open Lower, Turn Mixed As Oil Prices, Retail Stocks Rally

    Retail stocks were a bright spot and rising oil prices drove energy names higher, as stock futures braced for the pending next round in the U.S.-China trade war.

  • Ironwood's Linzess Gets Approval in Japan for New Indication
    Zacks27 days ago

    Ironwood's Linzess Gets Approval in Japan for New Indication

    Ironwood Pharmaceuticals (IRWD) along with its partner Astellas Pharma announces approval of Linzess in Japan for a new indication - chronic constipation.

  • Allergan Falls on FDA's Rejection of Uterine Fibroids Drug
    Zacks27 days ago

    Allergan Falls on FDA's Rejection of Uterine Fibroids Drug

    FDA rejects Allergan's (AGN) new drug application for Esmya for the treatment of abnormal uterine bleeding in women with uterine fibroids, citing safety issues.

  • Estimates and Recommendations for Allergan in August
    Market Realist28 days ago

    Estimates and Recommendations for Allergan in August

    Analysts expect Allergan’s (AGN) adjusted EPS to be $16.29 on revenue of $15.53 billion in 2018, a 2.6% fall in revenue compared to $15.94 billion in 2017. Analysts expect the company’s adjusted net income to fall in 2018 mainly due to a fall in its gross profit margin and partially offset by a decrease in its selling, general, and administrative expenses as well as its research and development expenses. Allergan’s stock price has fallen nearly 20.2% over the last 12 months, but it’s risen ~12.8% year-to-date in 2018.

  • Recent Developments at Allergan
    Market Realist28 days ago

    Recent Developments at Allergan

    Allergan (AGN) is developing a variety of products through internal programs as well as in collaboration with other companies. A few of the products it currently has under development are Cenicriviroc, Atogepant, Bimatoprost SR, Ubrogepant, Abicipar, Rapastinel, and Sarecycline.

  • Examining Amgen’s Revenue Trend in Q2 2018
    Market Realist29 days ago

    Examining Amgen’s Revenue Trend in Q2 2018

    As we discussed earlier, Amgen (AMGN) reported a 4% rise in its year-over-year revenue to ~$6.06 billion in the second quarter compared to $5.81 billion in the first quarter of 2017. Amgen surpassed analysts’ estimates for EPS and revenue in the second quarter, reporting non-GAAP (generally accepted accounting principles) EPS of $3.83 on revenue of ~$6.1 billion compared to the estimate of $3.54 on revenue of $5.7 billion.

  • Allergan’s International Business Segment in Q2 2018
    Market Realist29 days ago

    Allergan’s International Business Segment in Q2 2018

    Allergan’s (AGN) International Business segment includes the revenues from both its specialized therapeutics portfolio and its general products portfolio from outside US markets.

  • Allergan’s US General Medicines Segment in Q2 2018
    Market Realist29 days ago

    Allergan’s US General Medicines Segment in Q2 2018

    Allergan’s (AGN) US General Medicines segment includes women’s health products, central nervous system products, anti-infective products, gastrointestinal products, and diversified brands.

  • Allergan’s US Specialized Therapeutics Segment in Q2 2018
    Market Realist29 days ago

    Allergan’s US Specialized Therapeutics Segment in Q2 2018

    Allergan’s (AGN) US Specialized Therapeutics segment includes revenue from the US sales of specialized products, including eye care products, medical esthetics products, dermatology products, neuroscience products, and urology products.

  • A Closer Look at Allergan’s Business Segments in Q2 2018
    Market Realistlast month

    A Closer Look at Allergan’s Business Segments in Q2 2018

    As we discussed earlier, Allergan (AGN) has restructured its business over the last few years, and it now reports its revenues in three business segments.